Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery.

TOKYO, March 12, 2026 3 FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announces its investment in ...

VALANX Biotech (VALANX), a biotech company developing a technology for site-selectable, site-specific protein conjugation, ...

Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative dual payload bispecific antibody-drug conjugate ...

Will advance the biotech company's lead antibody-drug conjugate (ADC) program.

The market for Antibody-drug Conjugates (ADCs) in oncology presents significant opportunities with over 200 companies and 220 drugs in development globally. ADCs offer high specificity and reduced ...

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for ...

Explore the World ADC Conference highlights on antibody-drug conjugates and their impact on cancer therapy and clinical ...

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today released a new CEO Corner segment ...

Pfizer (PFE) looks undervalued at 8–9x forward earnings with a ~7% yield; see how Seagen, cost cuts and the pipeline could drive $36–42 upside—read now.

Actively recruiting Phase 1 trials for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 and MUC16-targeted ADC HWK-016 HWK-206 on track for planned IND submission in mid-2026 and Phase 1 start in ...